Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS

Study Identifier:
C08-003B
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: eculizumab
Date
Jul 2009 - Oct 2010
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 12 - 17 Years
Requirements Information
Sex
Female & Male
Age
12 - 17 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: eculizumab
Date
Jul 2009 - Oct 2010
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 12 - 17 Years years
Requirements Information

Protocol Summary

The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adolescent patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).

Trial Locations

Location
Status
Location
Toronto, Canada
Status
N/A
Location
Bois-Guillaume, France, 76230
Status
N/A
Location
Bordeaux, France, 33076
Status
N/A
Location
Lyon, France, 69437
Status
N/A
Location
Nantes, France, 44093
Status
N/A
Location
Paris, France, 75743
Status
N/A